SB 3199: JABSOM; Mental Health; Emerging Therapies; Task Force; Reports

A BILL FOR AN ACT

RELATING TO MENTAL HEALTH.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

     SECTION 1.  The legislature finds that there is an urgent need to address the mental health crisis affecting the residents of the State, particularly among veterans, first responders, and trauma survivors.  Suicide continues to be a leading cause of preventable death, and the State must explore all safe and effective treatment options supported by scientific evidence.

     The legislature furthers finds that the United States Food and Drug Administration has granted breakthrough therapy designation to several emerging treatments, including 3,4‑methylenedioxymethamphetamine (MDMA)-assisted therapy for post-traumatic stress disorder and psilocybin-assisted therapy for treatment‑resistant depression, in recognition of their potential to provide significant improvements over existing interventions.  As federal rescheduling and approval of these therapies are anticipated, the State must proactively prepare public health, clinical, and research systems for safe and equitable implementation.

     The legislature also finds that several states, including New Mexico, Texas, Oregon, and Connecticut, have already taken meaningful steps toward establishing frameworks for clinical research, pilot programs, or medical access pathways for emerging mental health therapies.  Without similar action, Hawaii risks falling behind and limiting access for residents and communities most affected by trauma.

     Accordingly, the purpose of this Act is to establish a two‑year mental health emerging therapies task force within the university of Hawaii at Manoa John A. Burns school of medicine to prepare the State for the integration of federally rescheduled breakthrough therapies.

     SECTION 2.  (a)  There is established the mental health emerging therapies task force within the university of Hawaii at Manoa John A. Burns school of medicine.

     (b)  The task force shall consist of the following members:

     (1)  A representative from the John A. Burns school of medicine at the university of Hawaii at Manoa, who shall serve as the chair of the task force;

     (2)  A representative from the Thompson school of social work and public health at the university of Hawaii at Manoa with demonstrated history and expertise in breakthrough and emerging therapies for therapeutic applications;

     (3)  A representative from the department of health's alcohol and drug abuse division;

     (4)  A representative from the department of health's adult mental health division;

     (5)  A representative from the department of the attorney general;

     (6)  A representative from the office of wellness and resilience;

     (7)  Seven members to be invited by the chair, who shall consist of:

          (A)  A representative from a veteran-serving institution;

          (B)  A representative from a Native Hawaiian health organization;

          (C)  One member with expertise in controlled‑substances laws and regulations;

          (D)  Two licensed psychiatrists or psychologists with expertise in trauma and post-traumatic stress disorder; and

          (E)  Two community members with lived experience as veterans, first responders, or family caregivers; and

     (8)  Any other member the chair deems appropriate, to be invited by the chair to participate in the task force.

     (c)  The task force shall:

     (1)  Prepare the State for federal rescheduling and medical approval of 3,4‑methylenedioxymethamphetamine (MDMA), psilocybin, and other drugs or treatments designated as breakthrough therapies by the United States Food and Drug Administration;

     (2)  Identify opportunities and requirements for expanding local clinical trials, investigator-initiated research, and university-based research partnerships;

     (3)  Develop educational partnerships to help expand awareness of clinical research opportunities for potential beneficiaries of breakthrough therapies;

     (4)  Recommend training, certification, and workforce development pathways for licensed professionals who may administer or support emerging therapies;

     (5)  Evaluate best practices from other jurisdictions regarding patient safety, culturally-informed care, equity, access, and harm reduction;

     (6)  Develop a statewide implementation roadmap for integrating emerging therapies pending federal approval; and

     (7)  Make legislative, administrative, and other recommendations to support long-term adoption of mental health emerging therapies in the State.

     (d)  The university of Hawaii at Manoa John A. Burns school of medicine shall provide administrative, technical, and research support to the task force.

     (e)  Administrative placement of the task force within the university of Hawaii at Manoa John A. Burns school of medicine shall not be construed to transfer, delegate, diminish, expand, or otherwise modify any regulatory, enforcement, licensing, scheduling, or rulemaking authority vested in the department of health, board of pharmacy, or any other state agency.  All statutory authority relating to controlled substances, professional licensure, and public health regulation shall remain with the appropriate executive branch agencies as provided by law.

     (f)  The task force may form working groups, invite subject matter experts, and contract with third-party organizations to carry out its duties under this section.

     (g)  Members of the task force shall serve without compensation but may be reimbursed for reasonable expenses, including travel expenses, necessary for their duties.

     (h)  The task force shall submit to the legislature:

     (1)  An interim report of its findings and recommendations, including any proposed legislation, no later than twenty days prior to the convening of the regular session of 2027; and

     (2)  A final report of its findings and recommendations, including any proposed legislation, no later than twenty days prior to the convening of the regular session of 2028.

     (i)  For the purposes of this section:

     "Breakthrough therapy" means any drug or treatment that has received breakthrough therapy designation by the United States Food and Drug Administration for a mental health or behavioral health condition.

     "Clinical trial" means any phase II or phase III trials regulated by the United States Food and Drug Administration, investigator-initiated trials, or state-authorized research studies designed to evaluate safety, efficacy, treatment delivery, or implementation models.

     "Emerging therapy" means therapy using any psychedelic or entactogenic compound therapy that:

     (1)  Is undergoing clinical trials regulated by the United States Food and Drug Administration;

     (2)  Has been approved for marketing by the United States Food and Drug Administration; or

     (3)  Has been rescheduled or authorized for medical use under state law.

     "Psychedelic" means a substance that produces altered states of consciousness with potential therapeutic benefit, including psilocybin, MDMA, and ibogaine.

     SECTION 3.  If any drug or treatment designated as a breakthrough therapy by the United States Food and Drug Administration is scheduled, rescheduled, or descheduled as a controlled substance under federal law, the narcotics enforcement division of the department of law enforcement shall similarly control, reschedule, or deschedule the drug or treatment in accordance with section 329-11, Hawaii Revised Statutes, within thirty days after publication of the applicable notice in the Federal Register or interim final order.

     SECTION 4.  This Act shall take effect on January 30, 2050, and shall be repealed on June 30, 2028.

Report Title:

JABSOM; Mental Health; Emerging Therapies; Task Force; Reports

Description:

Establishes the Mental Health Emerging Therapies Task Force within the University of Hawaii at Manoa John A. Burns School of Medicine to prepare the State for the integration of breakthrough therapies, expansion of pathways for clinical trials and clinical research, and development of policy recommendations for safe, ethical, and culturally informed implementation of emerging therapies.  Requires reports to the Legislature.  Sunsets 6/30/2028.  Effective 1/30/2050.  (HD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

A BILL FOR AN ACT

RELATING TO MENTAL HEALTH.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

     SECTION 1.  The legislature finds that addressing the mental health crisis affecting the residents of the State, particularly among veterans, first responders, and trauma survivors, is urgent.  Suicide continues to be a leading cause of preventable death, and the State must explore all safe and effective treatment options supported by scientific evidence.

     The legislature furthers finds that the United States Food and Drug Administration has granted breakthrough therapy designation to several emerging treatments, including 3,4‑methylenedioxymethamphetamine (MDMA)-assisted therapy for post-traumatic stress disorder and psilocybin-assisted therapy for treatment‑resistant depression, in recognition of their potential to provide significant improvements over existing interventions.  As federal rescheduling and approval of these therapies are anticipated, the State must proactively prepare public health, clinical, and research systems for safe and equitable implementation.

     The legislature also finds that several states, including New Mexico, Texas, Oregon, and Connecticut, have already taken meaningful steps toward establishing frameworks for clinical research, pilot programs, or medical access pathways for emerging mental health therapies.  Without similar action, Hawaii risks falling behind and limiting access for residents and communities most affected by trauma.

     Accordingly, the purpose of this Act is to establish a two‑year mental health emerging therapies task force within an entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education, charged with preparing the State for the integration of federally rescheduled breakthrough therapies, expanding pathways for clinical trials and clinical research in the State, and developing policy recommendations for safe, ethical, and culturally-informed implementation.

     SECTION 2.  (a)  There is established the mental health emerging therapies task force within an entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education.

     (b)  The task force shall consist of the following thirteen members:

     (1)  One member representing the Thompson school of social work and public health at the university of Hawaii at Manoa with demonstrated history and expertise in breakthrough and emerging therapies for therapeutic applications, who shall serve as the chair of the taskforce;

     (2)  One member representing the department of health's alcohol and drug abuse division;

     (3)  One member representing the department of health's adult mental health division;

     (4)  One member representing the department of the attorney general;

     (5)  One member representing the office of wellness and resilience;

     (6)  One member representing the John A. Burns school of medicine at the university of Hawaii at Manoa; and

     (7)  Seven members to be invited by the chair, comprising:

          (A)  One member representing a veteran-serving institution;

          (B)  One member representing a Native Hawaiian health organization;

          (C)  One member representing an expert in controlled‑substances laws and regulations;

          (D)  Two licensed psychiatrists or psychologists with expertise in trauma and post-traumatic stress disorder; and

          (E)  Two community members with lived experience as veterans, first responders, or family caregivers.

     The chair may invite any other stakeholder the chair deems appropriate to participate in the task force.

     (c)  The task force shall:

     (1)  Prepare the State for federal rescheduling and medical approval of 3,4‑methylenedioxymethamphetamine (MDMA), psilocybin, and other drugs or treatments designated as breakthrough therapies by the United States Food and Drug Administration;

     (2)  Identify opportunities and requirements for expanding local clinical trials, investigator-initiated research, and university-based research partnerships;

     (3)  Develop educational partnerships to help expand awareness of clinical research opportunities for potential beneficiaries of breakthrough therapies;

     (4)  Recommend training, certification, and workforce development pathways for licensed professionals who may administer or support emerging therapies;

     (5)  Evaluate best practices from other jurisdictions regarding patient safety, culturally-informed care, equity, access, and harm reduction;

     (6)  Develop a statewide implementation roadmap for integrating emerging therapies pending federal approval; and

     (7)  Make legislative, administrative, and other recommendations to support long-term adoption of mental health emerging therapies in the State.

     (d)  An entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education shall provide administrative, technical, and research support to the task force.

     (e) Administrative placement of the task force within an entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education shall not be construed to transfer, delegate, diminish, expand, or otherwise modify any regulatory, enforcement, licensing, scheduling, or rulemaking authority vested in the department of health, the board of pharmacy, or any other state agency.  All statutory authority relating to controlled substances, professional licensure, and public health regulation shall remain with the appropriate executive branch agencies as provided by law.

     (f)  The task force may form working groups, invite subject matter experts, and contract with third-party organizations to carry out its duties under this section.

     (g)  Members of the task force shall serve without compensation but may be reimbursed for reasonable expenses, including travel expenses, necessary for their duties.

     (h)  The task force shall submit to the legislature:

     (1)  An interim report of its findings and recommendations, including any proposed legislation, no later than twenty days prior to the convening of the regular session of 2027; and

     (2)  A final report of its findings and recommendations, including any proposed legislation, no later than twenty days prior to the convening of the regular session of 2028.

     (i)  For the purposes of this section:

     "Breakthrough therapy" means any drug or treatment that has received breakthrough therapy designation by the United States Food and Drug Administration for a mental health or behavioral health condition.

     "Clinical trial" means any phase II or phase III trials regulated by the United States Food and Drug Administration, investigator-initiated trials, or state-authorized research studies designed to evaluate safety, efficacy, treatment delivery, or implementation models.

     "Emerging therapy" means therapy using any psychedelic or entactogenic compound therapy that:

     (1)  Is undergoing clinical trials regulated by the United States Food and Drug Administration;

     (2)  Has been approved for marketing by the United States Food and Drug Administration; or

     (3)  Has been rescheduled or authorized for medical use under state law.

     "Psychedelic" means a substance that produces altered states of consciousness with potential therapeutic benefit, including psilocybin, MDMA, and ibogaine.

     SECTION 3.  If any drug or treatment designated as a breakthrough therapy by the United States Food and Drug Administration is scheduled, rescheduled, or descheduled as a controlled substance under federal law, the board of pharmacy shall similarly control, reschedule, or deschedule the drug or treatment in accordance with section 329-11, Hawaii Revised Statutes, within ninety days after publication of the applicable notice in the Federal Register or interim final order.

     SECTION 4.  This Act shall take effect on January 30, 2050, and shall be repealed on June 30, 2028.

Report Title:

Mental Health; Emerging Therapies; Task Force; Reports

Description:

Establishes the Mental Health Emerging Therapies Task Force to prepare the State for the integration of breakthrough therapies, expansion of pathways for clinical trials and clinical research, and development of policy recommendations for safe, ethical, and culturally informed implementation of emerging therapies.  Requires reports to the Legislature.  Sunsets 6/30/2028.  Effective 1/30/2050.  (SD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

A BILL FOR AN ACT

relating to mental health.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

     SECTION 1.  The legislature finds that addressing the mental health crisis affecting the residents of the State, particularly among veterans, first responders, and trauma survivors, is urgent.  Suicide continues to be a leading cause of preventable death, and the State must explore all safe and effective treatment options supported by scientific evidence.

     The legislature furthers finds that the United States Food and Drug Administration has granted breakthrough therapy designation to several emerging treatments, including 3,4‑methylenedioxymethamphetamine (MDMA)-assisted therapy for post-traumatic stress disorder and psilocybin-assisted therapy for treatment‑resistant depression, in recognition of their potential to provide significant improvements over existing interventions.  As federal rescheduling and approval of these therapies are anticipated, the State must proactively prepare public health, clinical, and research systems for safe and equitable implementation.

     The legislature also finds that several states, including New Mexico, Texas, Oregon, and Connecticut, have already taken meaningful steps toward establishing frameworks for clinical research, pilot programs, or medical access pathways for emerging mental health therapies.  Without similar action, Hawaii risks falling behind and limiting access for residents and communities most affected by trauma.

     Accordingly, the purpose of this Act is to establish a two‑year mental health emerging therapies task force within the department of health, charged with preparing the State for the integration of federally rescheduled breakthrough therapies, expanding pathways for clinical trials and clinical research in the State, and developing policy recommendations for safe, ethical, and culturally-informed implementation.

     SECTION 2.  (a)  There is established the mental health emerging therapies task force within the department for administrative purposes only.

     (b)  The task force shall consist of the following thirteen members:

     (1)  One member representing the Thompson school of social work and public health at the university of Hawaii at Manoa with demonstrated history and expertise in breakthrough and emerging therapies for therapeutic applications, who shall serve as the chair of the taskforce;

     (2)  One member representing the department of health's alcohol and drug abuse division;

     (3)  One member representing the department of health's adult mental health division;

     (4)  One member representing the department of the attorney general;

     (5)  One member representing the office of wellness and resilience;

     (6)  One member representing the John A. Burns school of medicine at the university of Hawaii at Manoa; and

     (7)  Seven members to be invited by the chair, comprising:

          (A)  One member representing a veteran-serving institution;

          (B)  One member representing a Native Hawaiian health organization;

          (C)  One member representing an expert in controlled‑substances laws and regulations;

          (D)  Two licensed psychiatrists or psychologists with expertise in trauma and post-traumatic stress disorder; and

          (E)  Two community members with lived experience as veterans, first responders, or family caregivers.

     The chair may invite any other stakeholder the chair deems appropriate to participate in the task force.

     (c)  The task force shall:

     (1)  Prepare the State for federal rescheduling and medical approval of 3,4‑methylenedioxymethamphetamine (MDMA), psilocybin, and other drugs or treatments designated as breakthrough therapies by the United States Food and Drug Administration;

     (2)  Identify opportunities and requirements for expanding local clinical trials, investigator-initiated research, and university-based research partnerships;

     (3)  Develop educational partnerships to help expand awareness of clinical research opportunities for potential beneficiaries of breakthrough therapies;

     (4)  Recommend training, certification, and workforce development pathways for licensed professionals who may administer or support emerging therapies;

     (5)  Evaluate best practices from other jurisdictions regarding patient safety, culturally-informed care, equity, access, and harm reduction;

     (6)  Develop a statewide implementation roadmap for integrating emerging therapies pending federal approval; and

     (7)  Make legislative, administrative, and other recommendations to support long-term adoption of mental health emerging therapies in the State.

     (d)  The department shall provide administrative, technical, and research support to the task force.

     (e)  The task force may form working groups, invite subject matter experts, and contract with third-party organizations to carry out its duties under this section.

     (f)  Members of the task force shall serve without compensation but may be reimbursed for reasonable expenses, including travel expenses, necessary for their duties.

     (g)  The task force shall submit to the legislature:

     (1)  An interim report of its findings and recommendations, including any proposed legislation, no later than twenty days prior to the convening of the regular session of 2027; and

     (2)  A final report of its findings and recommendations, including any proposed legislation, no later than twenty days prior to the convening of the regular session of 2028.

     (h)  For the purposes of this section:

     "Breakthrough therapy" means any drug or treatment that has received breakthrough therapy designation by the United States Food and Drug Administration for a mental health or behavioral health condition.

     "Clinical trial" means any phase II or phase III trials regulated by the United States Food and Drug Administration, investigator-initiated trials, or state-authorized research studies designed to evaluate safety, efficacy, treatment delivery, or implementation models.

     "Department" means the department of health.

     "Emerging therapy" means therapy using any psychedelic or entactogenic compound therapy that:

     (1)  Is undergoing clinical trials regulated by the United States Food and Drug Administration;

     (2)  Has been approved for marketing by the United States Food and Drug Administration; or

     (3)  Has been rescheduled or authorized for medical use under state law.

     "Psychedelic" means a substance that produces altered states of consciousness with potential therapeutic benefit, including psilocybin, MDMA, and ibogaine.

     SECTION 3.  If any drug or treatment designated as a breakthrough therapy by the United States Food and Drug Administration is scheduled, rescheduled, or descheduled as a controlled substance under federal law, the board of pharmacy shall similarly control, reschedule, or deschedule the drug or treatment in accordance with section 329-11, Hawaii Revised Statutes, within ninety days after publication of the applicable notice in the Federal Register or interim final order.

     SECTION 4.  This Act shall take effect on July 1, 2026, and shall be repealed on June 30, 2028.

Report Title:

DOH; Mental Health; Emerging Therapies; Task Force; Reports

Description:

Establishes the Mental Health Emerging Therapies Task Force to prepare the State for the integration of breakthrough therapies, expansion of pathways for clinical trials and clinical research, and development of policy recommendations for safe, ethical, and culturally informed implementation of emerging therapies.  Requires reports to the Legislature.  Sunsets 6/30/2028.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

STAND. COM. REP. NO. 2856

Honolulu, Hawaii

RE:     S.B. No. 3199

        S.D. 1

Honorable Ronald D. Kouchi

President of the Senate

Thirty-Third State Legislature

Regular Session of 2026

State of Hawaii

Sir:

     Your Committee on Ways and Means, to which was referred S.B. No. 3199, S.D. 1, entitled:

"A BILL FOR AN ACT RELATING TO MENTAL HEALTH,"

begs leave to report as follows:

     The purpose and intent of this measure is to establish a two‑year Mental Health Emerging Therapies Task Force to proactively prepare the State to adopt new therapies, currently pending federal approval, for post-traumatic stress disorder, treatment-resistant depression, and other mental health conditions.

     More specifically, the purpose of the task force is to:

     (1)  Prepare the State for the integration of drugs and treatments designated as breakthrough therapies by the Untied States Food and Drug Administration;

     (2)  Identify opportunities and requirements to expand pathways for clinical trials, clinical research, and university-based research partnerships;

     (3)  Develop educational partnerships to ensure that potential beneficiaries of breakthrough therapies are aware of the availability of clinical trials;

     (4)  Recommend training, certification, and workforce development pathways for licensed professionals who may administer or support emerging therapies;

     (5)  Evaluate best practices from other jurisdictions regarding patient safety, culturally-informed care, equity, access, and harm reduction;

     (6)  Develop a statewide implementation roadmap for integrating the emerging therapies pending federal approval; and

     (7)  Develop legislative, administrative, and policy recommendations for the safe, ethical, and culturally informed implementation.

     Your Committee received written comments in support of this measure from the Department of Health, State Council on Mental Health, Disability and Communication Access Board, Office of Wellness and Resilience, Veterans Exploring Treatment Solutions, Hawaii Health and Harm Reduction Center, Aloha Integrative Mental Health, Hawaii Association of Professional Nurses, Clarity Project, Hawaii Radiant Health, Reason for Hope, Veteran Mental Health Leadership Coalition, and numerous individuals.

     Your Committee received written comments on this measure from the Attorney General and Hawaii Medical Association.

     Your Committee finds that addressing the mental health crisis affecting the residents of the State, particularly veterans, first responders, and trauma survivors, is urgent.  Within the State, suicide remains a leading cause of preventable death.  Your Committee believes the State must explore all safe and effective treatment options supported by scientific evidence.  The task force established by this measure will help inform mental health policymaking, expand clinical research, and make cutting-edge treatments available in Hawaii.

     As affirmed by the record of votes of the members of your Committee on Ways and Means that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 3199, S.D. 1, and recommends that it pass Third Reading.

Respectfully submitted on behalf of the members of the Committee on Ways and Means,

STAND. COM. REP. NO. 2551

Honolulu, Hawaii

RE:     S.B. No. 3199

        S.D. 1

Honorable Ronald D. Kouchi

President of the Senate

Thirty-Third State Legislature

Regular Session of 2026

State of Hawaii

Sir:

     Your Committee on Health and Human Services, to which was referred S.B. No. 3199 entitled:

"A BILL FOR AN ACT RELATING TO MENTAL HEALTH,"

begs leave to report as follows:

     The purpose and intent of this measure is to:

     (1)  Establish the Mental Health Emerging Therapies Task Force within the Department of Health to prepare the State for the:

          (A)  Integration of breakthrough therapies;

          (B)  Expansion of pathways for clinical trials and clinical research; and

          (C)  Development of policy recommendations for safe, ethical, and culturally informed implementation of emerging therapies; and

     (2)  Require reports to the Legislature.

     Your Committee received testimony in support of this measure from the Department of Health, Office of Wellness and Resilience, State Council on Mental Health, Clarity Project, MindWave Medicine, Veterans Exploring Treatment Solutions, Hawaiʻi Health & Harm Reduction Center, Drug Policy Forum of Hawaii, Reason for Hope, Veteran Mental Health Leadership Coalition, Hawaii Radiant Health, and forty individuals.

     Your Committee received testimony in opposition to this measure from one individual.

     Your Committee received comments on this measure from the Hawaiʻi Psychiatric Medical Association and Hawaii Medical Association.

     Your Committee finds that there is an urgent need to address the mental health crisis affecting the residents of the State, particularly among veterans, first responders, and trauma survivors.  Your Committee further finds that the United States Food and Drug Administration has granted breakthrough therapy designation to several emerging treatments, including 3,4‑methylenedioxymethamphetamine (MDMA)-assisted therapy for post‑traumatic stress disorder and psilocybin-assisted therapy for treatment-resistant depression, in recognition of their potential to provide significant improvements over existing interventions.  This measure establishes a responsible and evidence-based process that prepares the State for emerging therapies for individuals with serious mental illness.

     Your Committee notes the concerns raised in the testimony of the Department of Health that breakthrough therapies involving psychedelic or entactogenic compounds require sophisticated research design, strict adherence to human participant protections, comprehensive informed consent protocols, secure pharmaceutical handling and storage procedures, data safety monitoring processes, and institutional legal review for liability and compliance.  To this end, an existing entity with qualified research investigators, experienced clinical trial personnel, and established compliance frameworks is better positioned to ensure safe and effective outcomes rather than the Department of Health.  Therefore, amendments to this measure are necessary to address this concern.

Your Committee has amended this measure by:

     (1)  Changing the administrative placement of the Mental Health Emerging Therapies from within the Department of Health to an entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education and requiring that entity to provide administrative technical and research support to the task force;

     (2)  Inserting language to clarify that:

          (A)  Administrative placement of the task force within an entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education shall not be construed to transfer, delegate, diminish, expand, or otherwise modify any regulatory, enforcement, licensing, scheduling, or rulemaking authority vested in the Department of Health, Board of Pharmacy, or any other state agency; and

          (B)  All statutory authority relating to controlled substances, professional licensure, and public health regulation shall remain with the appropriate executive branch agencies as provided by law;

     (3)  Amending section 1 to reflect its amended purpose;

     (4)  Inserting an effective date of January 30, 2050, to encourage further discussion; and

     (5)  Making a technical, nonsubstantive amendment for the purposes of clarity and consistency.

     As affirmed by the record of votes of the members of your Committee on Health and Human Services that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 3199, as amended herein, and recommends that it pass Second Reading in the form attached hereto as S.B. No. 3199, S.D. 1, and be referred to your Committee on Ways and Means.

Respectfully submitted on behalf of the members of the Committee on Health and Human Services,